Ayala Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced that its management will present at two investor conferences: the Jefferies Virtual Global Healthcare Conference on June 3, 2020, at 10:30 am ET and the Raymond James 2020 Human Healthcare Innovation Conference on June 18, 2020, at 8:20 am ET. Both presentations will be accessible via a live webcast on Ayala's website, with archived replays available for 90 days. Ayala focuses on developing targeted therapies for rare and aggressive cancers, with key candidates AL101 and AL102 currently under clinical development.

REHOVOT, Israel and WILMINGTON, Del., June 01, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced Ayala management will present at two upcoming investor conferences:

• Jefferies Virtual Global Healthcare Conference: Wednesday, June 3, 2020 at 10:30 am ET.
• Raymond James 2020 Human Healthcare Innovation Conference: Thursday, June 18, 2020 at 8:20 am ET.

A live webcast of each presentation may be accessed by visiting the Investors and News section of Ayala’s website at www.ir.ayalapharma.com. An archived replay of each webcast will be available on the website for 90 days following the presentations.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala’s lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. For more information, visit www.ayalapharma.com

Contacts:

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

FAQ

What are the dates of Ayala Pharmaceuticals' upcoming investor presentations?

Ayala Pharmaceuticals will present at the Jefferies Virtual Global Healthcare Conference on June 3, 2020, and the Raymond James 2020 Human Healthcare Innovation Conference on June 18, 2020.

Where can I watch the Ayala Pharmaceuticals conference presentations?

The live webcasts of Ayala Pharmaceuticals' presentations can be accessed on the Investors and News section of their website.

What is the focus of Ayala Pharmaceuticals?

Ayala Pharmaceuticals focuses on developing small molecule therapeutics for patients suffering from rare and aggressive cancers.

What product candidates are under development by Ayala Pharmaceuticals?

Ayala Pharmaceuticals has two main product candidates in development: AL101 and AL102.

What designations has Ayala Pharmaceuticals' lead product candidate received?

Ayala's lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA.